Overall market sentiment has been down on Inhibikase Therapeutics Inc (IKT) stock lately. IKT receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Inhibikase Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IKT!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With IKT Stock Today?
Inhibikase Therapeutics Inc (IKT) stock is trading at $1.01 as of 3:39 PM on Tuesday, Sep 19, a decline of -$0.51, or -33.37% from the previous closing price of $1.52. The stock has traded between $0.95 and $1.52 so far today. Volume today is above average. So far 612,346 shares have traded compared to average volume of 34,701 shares.
To see InvestorsObserver's Sentiment Score for Inhibikase Therapeutics Inc click here.
More About Inhibikase Therapeutics Inc
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Click Here to get the full Stock Report for Inhibikase Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
